问题与更新：乳腺癌中雌激素受体-α、孕激素受体和 HER2 的评估。
Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.
机构信息
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
出版信息
Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55.
PMID:20436503
Abstract
There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.
摘要
目前有三种预后/预测生物标志物用于乳腺癌患者的常规临床管理，其评估是强制性的。它们包括雌激素受体-α（ERalpha）、孕激素受体（PgR）和 HER2 癌基因/癌蛋白。本文简要回顾了乳腺癌中 ERalpha、PgR 和 HER2 的评估，强调了最近的进展和持续存在的争议。
Zotero 插件